Silencing disease-causing proteins by covalently modifying their mRNA

Covalent translation inhibitors

Our small-molecule inhibitors selectively target and modify unique binding sites in the mRNA of disease-causing proteins to prevent expression by blocking the ribosome.

The mechanism of action is independent of the inherent biological functions of where the small molecule modifies the RNA and thus can be applied to any mRNA that has a druggable structured domain.

mRNA is an untapped class of small molecule targets

Our 3D structure-informed drug discovery platform identifies structured domains in mRNA of disease-causing proteins and validates them as effective target sites for small-molecule drugs.

The domains are large, stable, persistent and complex, with unique sequence and structural features that support selective, high-affinity small molecule binding.

We routinely identify druggable structured domains in human mRNA and have identified domains in the mRNA of >25 disease causing proteins across diverse protein classes.

We are the first mRNA-focused structure-guided drug discovery company

Though successfully applied to proteins, structure-guided drug discovery has been absent from small molecule programs targeting mRNA. Syrna has made revolutionary breakthroughs to change that by making 3D structures of mRNA accessible for target identification and for medicinal chemistry.

We reveal the 3D structure of drug binding sites in mRNA

3D structure provides a superior understanding of where to drug mRNA and how small molecules bind RNA. We use these critical insights to efficiently and effectively design our inhibitors.

Our lead programs and therapeutic area strategy

We have programs in early lead optimization targeting the mRNA of high value immunology and neurodegeneration disease causing proteins.

We have a broader asset base of druggable structured domains in the mRNA of important immunology, neurodegeneration, metabolic disease and oncology targets, many with chemistry assets.

Partnering opportunities

We welcome partnering opportunities to accelerate our portfolio.

Ready to learn more?

Discover how we are realizing the promise of mRNA as a small molecule drug target.

Email

News

Syrna Therapeutics Comes Out of Stealth with Covalent Translation Inhibitors Targeting mRNA

Shutting down the production of disease-causing proteins – by interfering with cellular translation – is the next great frontier in small-molecule drug discovery. Syrna Therapeutics was founded on the conviction that realizing this vision requires a fundamentally new approach and transformative capabilities. The company is leading this evolution by pioneering 3D structure-guided drug discovery for mRNA, coupled with a powerful universal mechanism for inhibiting translation that operates independently of the complex biology of each mRNA target.

Read more…